selected publications
- Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis. Neurology and therapy. 2023 Academic Article GET IT
- Epsilon toxin-producing Clostridium perfringens colonize the MS gut and epsilon toxin overcomes immune privilege. The Journal of clinical investigation. 2023 Academic Article GET IT
- Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS drugs. 2022 Academic Article GET IT
- Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis. Scientific reports. 2022 Academic Article GET IT
- Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Advances in therapy. 2021 Academic Article GET IT
- A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis. Molecular imaging and biology. 2020 Academic Article GET IT
-
Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions.
Journal of neuroimaging : official journal of the American Society of Neuroimaging.
2020
Academic Article
GET IT
Times cited: 9 -
Black African and Latino/a identity correlates with increased plasmablasts in MS.
Neurology(R) neuroimmunology & neuroinflammation.
2019
Academic Article
GET IT
Times cited: 15 -
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
BMC neurology.
2019
Academic Article
GET IT
Times cited: 41 -
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 204 -
Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Journal of neurology.
2018
Academic Article
GET IT
Times cited: 1 -
Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England).
2017
Article
GET IT
Times cited: 1 -
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
Multiple sclerosis and related disorders.
2017
Academic Article
GET IT
Times cited: 17 -
Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England).
2017
Academic Article
GET IT
Times cited: 7 -
Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.
Journal of neuroimaging : official journal of the American Society of Neuroimaging.
2016
Academic Article
GET IT
Times cited: 10 -
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Contemporary clinical trials.
2016
Academic Article
GET IT
Times cited: 53 -
A study of patients with aggressive multiple sclerosis at disease onset.
Neuropsychiatric disease and treatment.
2016
Academic Article
GET IT
Times cited: 10 -
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.
Neuropsychiatric disease and treatment.
2015
Information Resource
GET IT
Times cited: 8 -
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Drug design, development and therapy.
2013
Information Resource
GET IT
Times cited: 4 -
Fingolimod and cardiac risk: latest findings and clinical implications.
Therapeutic advances in drug safety.
2013
Academic Article
GET IT
Times cited: 24 -
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Archives of neurology.
2009
Academic Article
GET IT
Times cited: 43 -
Pediatric-onset multiple sclerosis in African-American black and European-origin white patients.
Pediatric neurology.
2009
Academic Article
GET IT
Times cited: 29 -
Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin.
European journal of neurology.
2008
Academic Article
GET IT
Times cited: 67 -
Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence.
Multiple sclerosis (Houndmills, Basingstoke, England).
2008
Academic Article
GET IT
Times cited: 8 -
Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
European journal of neurology.
2008
Academic Article
GET IT
Times cited: 43 -
Acute transverse myelitis with normal brain MRI : long-term risk of MS.
Journal of neurology.
2007
Academic Article
GET IT
Times cited: 26 -
Glatiramer acetate therapy for multiple sclerosis: a review.
Expert opinion on drug metabolism & toxicology.
2006
Information Resource
GET IT
Times cited: 22 -
Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm.
Parkinsonism & related disorders.
2004
Article
GET IT
Times cited: 9